Main variables	No. of employees	Total
No. of companies carrying out R&D in Biotechnology	Fewer than 250 employees	1.126
No. of companies carrying out R&D in Biotechnology	250 or more employees	108
No. of companies carrying out R&D in Biotechnology	Total 2020	1.233
%Companies according to biotechnology used: Genetic code	Fewer than 250 employees	30,9
%Companies according to biotechnology used: Genetic code	250 or more employees	40,2
%Companies according to biotechnology used: Genetic code	Total 2020	31,7
%Companies according to biotechnology used: Functional units	Fewer than 250 employees	37,4
%Companies according to biotechnology used: Functional units	250 or more employees	50,4
%Companies according to biotechnology used: Functional units	Total 2020	38,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Fewer than 250 employees	21,6
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	250 or more employees	34,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Total 2020	22,8
%Companies according to biotechnology used: Bioprocesses	Fewer than 250 employees	51,7
%Companies according to biotechnology used: Bioprocesses	250 or more employees	71
%Companies according to biotechnology used: Bioprocesses	Total 2020	53,4
%Companies according to biotechnology used: Sub-cellular organisms	Fewer than 250 employees	7,8
%Companies according to biotechnology used: Sub-cellular organisms	250 or more employees	16,8
%Companies according to biotechnology used: Sub-cellular organisms	Total 2020	8,6
%Companies according to biotechnology used: Bio-computing	Fewer than 250 employees	22,2
%Companies according to biotechnology used: Bio-computing	250 or more employees	22,3
%Companies according to biotechnology used: Bio-computing	Total 2020	22,3
%Companies according to biotechnology used: Nanobiotechnology	Fewer than 250 employees	10,5
%Companies according to biotechnology used: Nanobiotechnology	250 or more employees	12,1
%Companies according to biotechnology used: Nanobiotechnology	Total 2020	10,6
%Companies according to biotechnology used: Other	Fewer than 250 employees	14,7
%Companies according to biotechnology used: Other	250 or more employees	9,3
%Companies according to biotechnology used: Other	Total 2020	14,2
Companies in which biotechnology activities are: Main and/or exclusive	Fewer than 250 employees	590
Companies in which biotechnology activities are: Main and/or exclusive	250 or more employees	25
Companies in which biotechnology activities are: Main and/or exclusive	Total 2020	615
Companies in which biotechnology activities are: A secondary line of business	Fewer than 250 employees	156
Companies in which biotechnology activities are: A secondary line of business	250 or more employees	22
Companies in which biotechnology activities are: A secondary line of business	Total 2020	178
Companies in which biotechnology activities are: A tool necessary for production	Fewer than 250 employees	379
Companies in which biotechnology activities are: A tool necessary for production	250 or more employees	61
Companies in which biotechnology activities are: A tool necessary for production	Total 2020	440
%Company by field(s) of ultimate application of biotechnology use: Human Health	Fewer than 250 employees	46,2
%Company by field(s) of ultimate application of biotechnology use: Human Health	250 or more employees	46,5
%Company by field(s) of ultimate application of biotechnology use: Human Health	Total 2020	46,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Fewer than 250 employees	16,9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	250 or more employees	9,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Total 2020	16,2
%Company by field(s) of ultimate application of biotechnology use: Food products	Fewer than 250 employees	31,7
%Company by field(s) of ultimate application of biotechnology use: Food products	250 or more employees	35,6
%Company by field(s) of ultimate application of biotechnology use: Food products	Total 2020	32
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Fewer than 250 employees	25,6
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	250 or more employees	14,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Total 2020	24,6
%Company by field(s) of ultimate application of biotechnology use: Environment	Fewer than 250 employees	15,3
%Company by field(s) of ultimate application of biotechnology use: Environment	250 or more employees	17,7
%Company by field(s) of ultimate application of biotechnology use: Environment	Total 2020	15,5
%Company by field(s) of ultimate application of biotechnology use: Industry	Fewer than 250 employees	13,1
%Company by field(s) of ultimate application of biotechnology use: Industry	250 or more employees	11,1
%Company by field(s) of ultimate application of biotechnology use: Industry	Total 2020	12,9
Personnel in R&D in biotechnology (no. of persons)	Fewer than 250 employees	9.325
Personnel in R&D in biotechnology (no. of persons)	250 or more employees	4.119
Personnel in R&D in biotechnology (no. of persons)	Total 2020	13.444
Personnel in R&D in biotechnology (no. of persons): Researchers	Fewer than 250 employees	5.272
Personnel in R&D in biotechnology (no. of persons): Researchers	250 or more employees	2.106
Personnel in R&D in biotechnology (no. of persons): Researchers	Total 2020	7.378
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants	Fewer than 250 employees	4.053
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants	250 or more employees	2.013
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants	Total 2020	6.066
Personnel in R&D in biotechnology (no. of persons): women	Fewer than 250 employees	4.869
Personnel in R&D in biotechnology (no. of persons): women	250 or more employees	2.632
Personnel in R&D in biotechnology (no. of persons): women	Total 2020	7.501
Personnel in R&D in biotechnology (no. of persons): (women) Researchers	Fewer than 250 employees	2.752
Personnel in R&D in biotechnology (no. of persons): (women) Researchers	250 or more employees	1.299
Personnel in R&D in biotechnology (no. of persons): (women) Researchers	Total 2020	4.052
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants	Fewer than 250 employees	2.117
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants	250 or more employees	1.333
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants	Total 2020	3.450
Personnel in R&D in biotechnology (FTE)	Fewer than 250 employees	6.291,5
Personnel in R&D in biotechnology (FTE)	250 or more employees	3.110,4
Personnel in R&D in biotechnology (FTE)	Total 2020	9.401,9
Personnel in R&D in biotechnology (FTE): Researchers	Fewer than 250 employees	3.811,8
Personnel in R&D in biotechnology (FTE): Researchers	250 or more employees	1.586,5
Personnel in R&D in biotechnology (FTE): Researchers	Total 2020	5.398,3
Personnel in R&D in biotechnology (FTE): Technicians and assistants	Fewer than 250 employees	2.479,7
Personnel in R&D in biotechnology (FTE): Technicians and assistants	250 or more employees	1.523,9
Personnel in R&D in biotechnology (FTE): Technicians and assistants	Total 2020	4.003,6
Personnel in R&D in biotechnology (FTE): women	Fewer than 250 employees	3.385,8
Personnel in R&D in biotechnology (FTE): women	250 or more employees	2.040,5
Personnel in R&D in biotechnology (FTE): women	Total 2020	5.426,2
Personnel in R&D in biotechnology (FTE): (women) Researchers	Fewer than 250 employees	2.020,5
Personnel in R&D in biotechnology (FTE): (women) Researchers	250 or more employees	996
Personnel in R&D in biotechnology (FTE): (women) Researchers	Total 2020	3.016,4
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants	Fewer than 250 employees	1.365,3
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants	250 or more employees	1.044,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants	Total 2020	2.409,8
Internal expenditure on R&D (thousands of euros)	Fewer than 250 employees	586.635
Internal expenditure on R&D (thousands of euros)	250 or more employees	310.698
Internal expenditure on R&D (thousands of euros)	Total 2020	897.333
1) By nature of the expense: Current expenses	Fewer than 250 employees	520.977
1) By nature of the expense: Current expenses	250 or more employees	296.432
1) By nature of the expense: Current expenses	Total 2020	817.409
1.1) Remuneration to researchers	Fewer than 250 employees	182.849
1.1) Remuneration to researchers	250 or more employees	112.856
1.1) Remuneration to researchers	Total 2020	295.705
1.2) Remuneration to technicians and assistants	Fewer than 250 employees	90.123
1.2) Remuneration to technicians and assistants	250 or more employees	66.730
1.2) Remuneration to technicians and assistants	Total 2020	156.853
1.3) Other current expenses	Fewer than 250 employees	248.005
1.3) Other current expenses	250 or more employees	116.847
1.3) Other current expenses	Total 2020	364.852
2) By nature of the expense: Capital expenses	Fewer than 250 employees	65.658
2) By nature of the expense: Capital expenses	250 or more employees	14.266
2) By nature of the expense: Capital expenses	Total 2020	79.924
2.1) Land and buildings	Fewer than 250 employees	6.331
2.1) Land and buildings	250 or more employees	3.941
2.1) Land and buildings	Total 2020	10.272
2.2) Equipment and instruments	Fewer than 250 employees	46.970
2.2) Equipment and instruments	250 or more employees	9.640
2.2) Equipment and instruments	Total 2020	56.609
2.3) Acquisition of specific R&D software	Fewer than 250 employees	4.475
2.3) Acquisition of specific R&D software	250 or more employees	364
2.3) Acquisition of specific R&D software	Total 2020	4.839
2.4) Otros productos de propiedad intelectual específicos para I+D	Fewer than 250 employees	7.882
2.4) Otros productos de propiedad intelectual específicos para I+D	250 or more employees	321
2.4) Otros productos de propiedad intelectual específicos para I+D	Total 2020	8.203
1.1) By origin of the funds: Own funds	Fewer than 250 employees	406.605
1.1) By origin of the funds: Own funds	250 or more employees	206.492
1.1) By origin of the funds: Own funds	Total 2020	613.097
1.2) By origin of the funds: From companies	Fewer than 250 employees	62.831
1.2) By origin of the funds: From companies	250 or more employees	23.253
1.2) By origin of the funds: From companies	Total 2020	86.085
1.3) By origin of the funds: Public Administration funds	Fewer than 250 employees	71.590
1.3) By origin of the funds: Public Administration funds	250 or more employees	20.550
1.3) By origin of the funds: Public Administration funds	Total 2020	92.140
1.4) By origin of the funds: From Universities	Fewer than 250 employees	548
1.4) By origin of the funds: From Universities	250 or more employees	306
1.4) By origin of the funds: From Universities	Total 2020	853
1.5) By origin of the funds: From non profit private institutions	Fewer than 250 employees	2.496
1.5) By origin of the funds: From non profit private institutions	250 or more employees	2.185
1.5) By origin of the funds: From non profit private institutions	Total 2020	4.682
1.6) By origin of the funds: Foreign funds	Fewer than 250 employees	42.564
1.6) By origin of the funds: Foreign funds	250 or more employees	57.912
1.6) By origin of the funds: Foreign funds	Total 2020	100.476
Purchase of R&D services in biotechnology (thousands of euros)	Fewer than 250 employees	48.478
Purchase of R&D services in biotechnology (thousands of euros)	250 or more employees	36.533
Purchase of R&D services in biotechnology (thousands of euros)	Total 2020	85.011
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Fewer than 250 employees	23.128
Purchase of R&D services in biotechnology (thousands of euros): In Spain	250 or more employees	31.114
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Total 2020	54.243
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Fewer than 250 employees	25.350
Purchase of R&D services in biotechnology (thousands of euros): Abroad	250 or more employees	5.419
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Total 2020	30.768
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Fewer than 250 employees	40,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	250 or more employees	22,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Total 2020	39,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Fewer than 250 employees	11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	250 or more employees	14
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Total 2020	11,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Fewer than 250 employees	12,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	250 or more employees	8,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Total 2020	12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Fewer than 250 employees	10,8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	250 or more employees	11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Total 2020	10,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Fewer than 250 employees	14,7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	250 or more employees	10,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Total 2020	14,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Fewer than 250 employees	17,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	250 or more employees	7,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Total 2020	16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Fewer than 250 employees	15,2
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	250 or more employees	13,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Total 2020	15
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Fewer than 250 employees	36
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	250 or more employees	31
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Total 2020	36
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Fewer than 250 employees	47,2
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	250 or more employees	41
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Total 2020	46,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Fewer than 250 employees	19,3
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	250 or more employees	15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Total 2020	19
% Companies that have requested biotechnology patents in Biotechnology	Fewer than 250 employees	17,3
% Companies that have requested biotechnology patents in Biotechnology	250 or more employees	17,7
% Companies that have requested biotechnology patents in Biotechnology	Total 2020	17,3
Number of patents requested	Fewer than 250 employees	600
Number of patents requested	250 or more employees	81
Number of patents requested	Total 2020	681
% Companies with income of an international origin related to biotechnological activities	Fewer than 250 employees	23,6
% Companies with income of an international origin related to biotechnological activities	250 or more employees	16,8
% Companies with income of an international origin related to biotechnological activities	Total 2020	23
% Turnover representing income of an international origin related to biotechnological activities	Fewer than 250 employees	5,6
% Turnover representing income of an international origin related to biotechnological activities	250 or more employees	0,9
% Turnover representing income of an international origin related to biotechnological activities	Total 2020	1,6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Fewer than 250 employees	44,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	250 or more employees	69,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Total 2020	55,9
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Fewer than 250 employees	55,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	250 or more employees	30,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Total 2020	44,1
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Fewer than 250 employees	97,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	250 or more employees	67,6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Total 2020	83,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Fewer than 250 employees	1,1
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 or more employees	31,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total 2020	14,7
% Income of an international origin related with activities according to the classification: Operating source abroad	Fewer than 250 employees	0,7
% Income of an international origin related with activities according to the classification: Operating source abroad	250 or more employees	0,9
% Income of an international origin related with activities according to the classification: Operating source abroad	Total 2020	0,8
% Income of an international origin related with activities according to the classification: Other	Fewer than 250 employees	1,1
% Income of an international origin related with activities according to the classification: Other	250 or more employees	0
% Income of an international origin related with activities according to the classification: Other	Total 2020	0,6